Etienne Puymirat

Etienne Puymirat

Auto-generated profile, based on publicly available information

Etienne Puymirat

Cardiovascular Department, Hôpital Européen Georges-Pompidou, Université Paris-Cité, France (E.P., C.S., E.M.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
EPEtienne Puymirat
Etienne Puymirat
GTGuillaume Taldir
Guillaume Taldir
NANadia Aissaoui
Nadia Aissaoui
GLGilles LEMESLE
Gilles LEMESLE
LLLuc Lorgis
Luc Lorgis
NDNicolas Danchin
Nicolas Danchin

17 November 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EPEtienne Puymirat
Etienne Puymirat
LLLionel Lamhaut
Lionel Lamhaut
NBNicolas Bonnet
Nicolas Bonnet
NANadia Aissaoui
Nadia Aissaoui
PHPatrick Henry
Patrick Henry
NDNicolas Danchin
Nicolas Danchin
The use of opioids is recommended for pain relief in patients with myocardial infarction (MI) but may delay antiplatelet agent absorption, potentially leading to decreased treatment efficacy. In-hospital complications (death, non-fatal re-MI, stroke, stent thrombosis, and bleeding) and 1-year survival according to pre-hospital morphine use were assessed in 2438 ST-elevation MI (STEMI) patients from the French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2010. The analyses were replicated in the 1726 STEMI patients of the FAST-MI 2005 cohort, in which polymorphisms of CYP2C19 and ABCB1 had been assessed. Specific subgroup analyses taking into account these genetic polymorphisms were performed in patients pre-treated with thienopyridines. The 453 patients (19%) receiving morphine pre-hospital were younger, more often male, with a lower GRACE score and higher chest pain levels. After adjustment for baseline differences, in-hospital complications and 1-year survival (hazard ratio = 0.69; 95% confidence interval: 0.35–1.37) were not increased according to pre-hospital morphine use. After propensity score matching, 1-year survival according to pre-hospital morphine was also similar. Consistent results were found in the replication cohort, including in those receiving pre-hospital thienopyridines and whatever the genetic polymorphisms of CYP2C19 and ABCB1. In two independent everyday-life cohorts, pre-hospital morphine use in STEMI patients was not associated with worse in-hospital complications and 1-year mortality. Clinicaltrials.gov identifier: NCT00673036 (FAST-MI 2005); NCT01237418 (FAST-MI 2010).

28 October 2022 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
RGRodrigue Garcia
Rodrigue Garcia
EMEloi Marijon
Eloi Marijon
NKNicole Karam
Nicole Karam
KNKumar Narayanan
Kumar Narayanan
FAFrédéric Anselme
Frédéric Anselme
NDNicolas Danchin
Nicolas Danchin
Sudden cardiac arrest remains a major complication of acute myocardial infarction (AMI) and is frequently related to ventricular fibrillation (VF). Incidence and impact of VF among patients hospitalized for AMI were evaluated. Data from the FAST-MI programme consisting of 5 French nationwide prospective cohort studies between 1995 and 2015 were analysed, totally including 14 423 patients with AMI (66 ± 14 years, 72% males, 59% ST-elevation myocardial infarction). Overall, proportion of patients presenting in-hospital VF decreased from 3.9% in 1995 to 1.8% in 2015 (P < 0.001). One-year mortality decreased from 60.7% to 24.6% (P < 0.001). However, compared with patients who did not develop VF, the over-risk of 1-year mortality associated with VF was stable over time [hazard ratio (HR) 6.78, 95% confidence interval (CI) 5.03–9.14 in 1995 and HR 6.64, 95% CI 4.20–10.49 in 2015, P = 0.52]. This increased mortality in the VF group was mainly related to fatal events occurring prior to hospital discharge, representing 86.2% of 1-year mortality, despite the very low rate of implantable cardioverter defibrillator in the VF group (2.6%). This study demonstrates that in-hospital VF incidence and mortality in the setting of AMI have significantly decreased over the past 20 years. Nevertheless, VF remained steadily associated with approximately a 10-fold increased relative risk of in-hospital mortality, without an impact on post-discharge mortality. Beyond long-term cardiac defibrillation strategy, these results emphasize the need to identify in-hospital interventions to further reduce mortality in VF patients. ClinicalTrials.gov Identifier: NCT00673036, NCT01237418, NCT02566200 In-hospital ventricular fibrillation (VF) incidence and mortality in the setting of acute myocardial infarction have significantly decreased over the past 20 years. Nevertheless, VF remained steadily associated with a ∼10-fold increased relative risk of in-hospital mortality, without an impact on post-discharge mortality. FAST-MI, French registry of acute ST-elevation or non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; VF, ventricular fibrillation.

1 November 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
PDPierre Denormandie
Pierre Denormandie
TSTabassome Simon
Tabassome Simon
GCGuillaume Cayla
Guillaume Cayla
GSGabriel Steg
Gabriel Steg
GMGilles Montalescot
Gilles Montalescot
EPEtienne Puymirat
Etienne Puymirat
Background: In patients with ST-segment–elevation myocardial infarction and multivessel disease, percutaneous coronary intervention (PCI) for nonculprit lesions guided by fractional flow reserve (FFR) is superior to treatment of the culprit lesion alone. Whether deferring nonculprit PCI is safe in this specific context is questionable. We aimed to assess clinical outcomes at 1 year in ST-segment–elevation myocardial infarction patients with multivessel coronary artery disease and an FFR-guided strategy for nonculprit lesions, according to whether or not ≥1 PCI was performed. Methods: Outcomes were analyzed in patients of the randomized FLOWER-MI (Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction) trial in whom, after successful primary PCI, nonculprit lesions were assessed using FFR. The primary outcome was a composite of all-cause death, nonfatal myocardial infarction, and unplanned hospitalization with urgent revascularization at 1 year. Results: Among 1171 patients enrolled in this study, 586 were assigned to the FFR-guided group: 388 (66%) of them had ≥1 PCI, and 198 (34%) had no PCI. Mean FFR before decision (ie, PCI or not) of nonculprit lesions was 0.75±0.10 and 0.88±0.06, respectively. During follow-up, a primary outcome event occurred in 16 of 388 patients (4.1%) in patients with PCI and in 16 of 198 patients (8.1%) in patients without PCI (adjusted hazard ratio, 0.42 [95% CI, 0.20–0.88]; P =0.02). Conclusions: In patients with ST-segment–elevation myocardial infarction undergoing complete revascularization guided by FFR measurement, those with ≥1 PCI had lower event rates at 1 year, compared with patients with deferred PCI, suggesting that deferring lesions judged relevant by visual estimation but with FFR >0.80 may not be optimal in this context. Future randomized studies are needed to confirm these data. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02943954. Graphic A graphic abstract is available for this article.

1 December 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
MDMaria Pia Donataccio
Maria Pia Donataccio
EPEtienne Puymirat
Etienne Puymirat
BPBiljana Parapid
Biljana Parapid
GSGabriel Steg
Gabriel Steg
HEHélène Eltchaninoff
Hélène Eltchaninoff
TSTabassome Simon
Tabassome Simon

8 February 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
JGJose R. Gonzalez-Juanatey
Jose R. Gonzalez-Juanatey
GLGilles Lemesle
Gilles Lemesle
EPEtienne Puymirat
Etienne Puymirat
GDGregory Ducrocq
Gregory Ducrocq
MCMarine Cachanado
Marine Cachanado
FIfor the REALITY Investigators
for the REALITY Investigators